Stryker's (SYK) "Buy (B-)" Rating Reiterated at Weiss Ratings

Key Points

• Stryker's stock maintains its "buy (B-)" rating from Weiss Ratings, amid ongoing evaluations from multiple analysts, reflecting a strong market position.
• The company reported a quarterly earnings per share of $3.13, surpassing estimates, with a revenue increase of 11.1% year-over-year, signaling a healthy growth trajectory.
• Insider transactions included Director Ronda E. Stryker selling 200,000 shares leading to a 5.84% decrease in her position, indicating possible adjustments in insider holdings.

Stryker (NYSE:SYK - Get Free Report)'s stock had its "buy (b-)" rating reissued by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts also recently commented on SYK. Needham & Company LLC increased their price objective on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Rothschild & Co Redburn began coverage on shares of Stryker in a report on Thursday, September 18th. They set a "neutral" rating and a $420.00 price target on the stock. Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Wall Street Zen downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. Finally, Rothschild Redb upgraded shares of Stryker to a "hold" rating in a research note on Thursday, September 18th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, Stryker presently has an average rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Stock Up 1.7%

NYSE SYK traded up $6.11 on Wednesday, hitting $375.35. 1,509,253 shares of the stock traded hands, compared to its average volume of 1,488,036. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average of $380.99 and a 200 day moving average of $378.83. The company has a market capitalization of $143.50 billion, a P/E ratio of 49.72, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company's revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, analysts expect that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stryker

Hedge funds have recently modified their holdings of the business. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Stryker in the second quarter valued at $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the 2nd quarter valued at about $28,000. Sachetta LLC raised its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after buying an additional 27 shares during the period. Kilter Group LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at about $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in Stryker during the 2nd quarter worth approximately $29,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.